Melanie Senior

Learn More
Individual kernel weight is an important trait for maize yield determination. We have identified genomic regions controlling this trait by using the B73xMo17 population; however, the effect of genetic background on control of this complex trait and its physiological components is not yet known. The objective of this study was to understand how genetic(More)
ABSTRACT A random set of recombinant inbred (RI) lines (F2:7) derived from the cross of the inbred lines Mo17 (resistant) and B73 (susceptible) were evaluated for resistance to southern leaf blight (SLB) caused by Cochliobolus heterostrophus race O. The RI lines were genotyped at a total of 234 simple sequence repeat, restriction fragment length(More)
largest US health insurer, spent $100 million on Sovaldi in its first 3 months on the market—a multiple of what it expected, though partly due to pent-up demand. Payers could restrict uptake by allowing only the sickest patients onto Sovaldi, such as those with liver fibrosis or on the brink of a liver transplant. “Payers can be more aggressive than they(More)
volume 32 NumBeR 9 SePTemBeR 2014 nature biotechnology Google’s latest generation of wearable technology is a ‘smart’ contact lens that may eventually provide noninvasive blood glucose monitoring for diabetics, and correct vision in individuals with presbyopia. That’s why Alcon, the eye-care division of Swiss pharma Novartis, signed up to co-develop the(More)
US Food and Drug Administration (FDA)’s decision in late October 2013 to suspend marketing of Ariad’s chronic myeloid leukemia (CML) drug Iclusig (ponatinib) sent shockwaves through the industry. Most clinicians weren’t expecting a full-scale suspension, and neither apparently was the financial community, which sent the Cambridge, Massachusetts, biotech’s(More)
On November 19, 2014, the Cystic Fibrosis Foundation (CFF), a charity, received its biggest paycheck ever, for $3.3 billion. It wasn’t a donation, but a business deal. New York– based investment firm Royalty Pharma was paying for rights to future royalties on cystic fibrosis drugs developed, with CFF’s help, by Boston-based Vertex Pharmaceuticals. The(More)
unquestionably built momentum for the company’s subsequent $15-million public offering, helped increase demand and “maybe moved some [investors] that were on the fence over to our side,” suggests McEnany. Indeed, “it helped us make our decision” to invest in Catalyst, confirms Mark Charest, vice president at New Leaf Venture Partners in San Mateo,(More)
The $5.2-billion sale of Ariad Pharmaceuticals to Japan’s Takeda Pharmaceutical, announced in January 2017, marks the end of an era. The 25-year-old, Cambridge, Massachusetts–based biotech, founded when the sector was still in its infancy, was one of a clutch of biotech firms that managed to get a drug to market alone, in this case having designed and(More)
269 perspective,” notes executive vice president of R&D Sean Harper on a February 7 strategy call. Amgen, like other innovators, including New York–based Pfizer and Merck of Whitehouse Station, New Jersey, are hedging their bets in joining the biosimilars battlefield. Merck is farming most of the risk to partners. After several false starts in biosimilars,(More)